retatrutide phase 3 trials VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Phase 3 Results: Trials,
Description
A more likely explanation, he says, is telogen effluvium, a temporary shedding condition triggered by stress
Some patients never experience it, while others doindividual variation is normal and unrelated to how well the medication works
Severe allergic reactions: Go to the nearest emergency room for any unusual swelling, difficulty breathing, or signs of anaphylaxis
Additionally, participants completed a three-day food record using the 2024 version of the Automated Self-Administered Dietary Assessment Tool, which was used to calculate each individual's average intake
